Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Quanterix Corporation is a medical devices business based in the US. Quanterix Corporation shares (QTRX) are listed on the NASDAQ and all prices are listed in US Dollars. Quanterix Corporation employs 314 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$50.22|
|52-week range||$36.16 - $92.57|
|50-day moving average||$48.78|
|200-day moving average||$53.87|
|Wall St. target price||$76.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.90|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-15)||-2.88%|
|1 month (2021-09-24)||-5.23%|
|3 months (2021-07-23)||-5.62%|
|6 months (2021-04-23)||-17.31%|
|1 year (2020-10-23)||23.73%|
|2 years (2019-10-24)||142.37%|
|3 years (2018-10-24)||207.16%|
|5 years (2016-10-20)||N/A|
|Revenue TTM||$110.1 million|
|Gross profit TTM||$48.9 million|
|Return on assets TTM||-5.5%|
|Return on equity TTM||-10.27%|
|Market capitalisation||$1.8 billion|
TTM: trailing 12 months
There are currently 1.2 million Quanterix Corporation shares held short by investors – that's known as Quanterix Corporation's "short interest". This figure is 5% up from 1.1 million last month.
There are a few different ways that this level of interest in shorting Quanterix Corporation shares can be evaluated.
Quanterix Corporation's "short interest ratio" (SIR) is the quantity of Quanterix Corporation shares currently shorted divided by the average quantity of Quanterix Corporation shares traded daily (recently around 200942.04355109). Quanterix Corporation's SIR currently stands at 5.97. In other words for every 100,000 Quanterix Corporation shares traded daily on the market, roughly 5970 shares are currently held short.
However Quanterix Corporation's short interest can also be evaluated against the total number of Quanterix Corporation shares, or, against the total number of tradable Quanterix Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Quanterix Corporation's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Quanterix Corporation shares in existence, roughly 30 shares are currently held short) or 0.0389% of the tradable shares (for every 100,000 tradable Quanterix Corporation shares, roughly 39 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Quanterix Corporation.
Find out more about how you can short Quanterix Corporation stock.
We're not expecting Quanterix Corporation to pay a dividend over the next 12 months.
Over the last 12 months, Quanterix Corporation's shares have ranged in value from as little as $36.16 up to $92.57. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Quanterix Corporation's is 1.4947. This would suggest that Quanterix Corporation's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Quanterix Corporation, a life sciences company, develops and markets digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a sensitive automated multiplex protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection technology in various applications, including direct detection of nucleic acids. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assay kits and other consumables such as reagents. In addition, it offers contract research services, including sample testing, homebrew assay development, and custom development services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct sales force, support organizations, and distributors or sales agents.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.